-
公开(公告)号:EP3871672B1
公开(公告)日:2022-08-17
申请号:EP21153980.4
申请日:2021-01-28
IPC分类号: A61K31/366 , C07D311/78 , A61K47/32 , A61K47/10 , A61K36/30 , A61K9/127 , A61K9/06 , A61K45/06 , A61K36/00 , A61K47/46 , A61K9/00 , A61P19/00 , A61P19/08 , A61P19/02 , A61P29/00 , A61K31/216 , A61K31/192 , A61K31/235
-
公开(公告)号:EP4039279A1
公开(公告)日:2022-08-10
申请号:EP20871804.9
申请日:2020-10-02
发明人: NARITA, Muneto , ISHII, Kensuke , SHIMURA, Akihito
IPC分类号: A61K47/61 , A61P13/10 , A61P43/00 , A61K45/00 , G01N33/15 , G01N33/50 , A61K31/192 , A61K31/196 , A61K31/495 , A61K31/575 , A61K31/58
摘要: As a system that enables effective delivery of a pharmaceutical active ingredient to a submucosal tissue of the bladder, a transmucosal delivery system including a conjugate of a hydrophobic compound containing the pharmaceutical active ingredient and chondroitin sulfate is provided.
-
73.
公开(公告)号:EP4037766A1
公开(公告)日:2022-08-10
申请号:EP20789025.2
申请日:2020-10-02
发明人: SCHLOTAWA, Lars , KETTWIG, Matthias , RADHAKRISHNAN, Karthikeyan , DIERKS, Thomas , GÄRTNER, Jutta , BAUD, Matthias
IPC分类号: A61P3/00 , A61K31/15 , A61K31/192 , A61K31/415 , A61K31/4436 , A61K45/06 , A61P43/00
-
74.
公开(公告)号:EP3302514B1
公开(公告)日:2022-07-06
申请号:EP16804027.7
申请日:2016-05-25
发明人: SIMARD, J., Marc , JACOBSON, Sven
IPC分类号: A61K31/196 , A61K38/00 , C12N15/11 , A61K48/00 , A61K39/395 , A61K31/175 , A61K31/18 , A61K31/05 , A61K31/132 , A61K31/192 , A61K31/64 , C12N15/113 , A61P9/00
-
公开(公告)号:EP4009946A1
公开(公告)日:2022-06-15
申请号:EP20760708.6
申请日:2020-08-07
发明人: WILSON, Glynn , HUGLI, Tony
IPC分类号: A61K9/00 , A61K31/05 , A61K31/164 , A61K31/167 , A61K31/192 , A61K31/198 , A61K31/352 , A61K31/353 , A61P17/00 , A61P29/00
-
公开(公告)号:EP3273952B1
公开(公告)日:2022-06-15
申请号:EP16769429.8
申请日:2016-03-18
IPC分类号: A61K31/10 , A61K31/445 , A61K31/473 , A61K31/60 , A61K45/06 , A61K9/00 , A61K31/192 , A61K31/196 , A61K31/407 , A61P1/02 , A61P3/02 , A61P29/00 , A61P39/02 , A61P43/00 , A61K31/4545 , A61K31/495 , A61K31/603
-
公开(公告)号:EP3996698A1
公开(公告)日:2022-05-18
申请号:EP20733929.2
申请日:2020-06-16
申请人: DSM IP Assets B.V.
IPC分类号: A61K31/192 , A61K31/202 , A61K31/525 , A61P1/00
-
公开(公告)号:EP3386466B1
公开(公告)日:2022-05-11
申请号:EP16813204.1
申请日:2016-12-05
IPC分类号: A61K31/4045 , A61K31/192 , A61P25/06 , A61P25/24 , A61P25/08 , A61P25/28 , A61P25/16 , A61K8/27 , A61K8/44 , A61Q11/02 , A61K33/00 , A61K31/198
-
公开(公告)号:EP3989957A1
公开(公告)日:2022-05-04
申请号:EP20742163.7
申请日:2020-06-26
IPC分类号: A61K31/167 , A61K31/192 , A61K31/235 , A61P25/00 , A61P25/02 , A61P25/20 , A61P25/28
-
公开(公告)号:EP3988091A1
公开(公告)日:2022-04-27
申请号:EP21214529.6
申请日:2016-08-08
摘要: A pharmaceutical composition for treatment of inflammation or pain or chronic inflammation is liquid at normal human body temperature, namely 37°C, solid at room temperature, namely 20°C, and comprises: a) 25% to 31 % by weight of a non-steroidal anti-inflammatory drug (NSAID); b) 34% to 40% by weight of a lipid which is solid at room temperature, namely 20°C; c) 22% to 28% by weight of a lipid which is a liquid at room temperature, namely 20°C; and d) 7% to 13% by weight of a stabilizing agent comprising liquid glycol polymer.
-
-
-
-
-
-
-
-
-